ABVC Biopharma Inc
NASDAQ:ABVC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ABVC Biopharma Inc
Cash & Cash Equivalents
ABVC Biopharma Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Cash & Cash Equivalents
$681.5k
|
CAGR 3-Years
96%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$12B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
27%
|
CAGR 10-Years
25%
|
|
|
Incyte Corp
NASDAQ:INCY
|
Cash & Cash Equivalents
$3.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Cash & Cash Equivalents
$383.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Cash & Cash Equivalents
$1.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
ABVC Biopharma Inc
Glance View
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
See Also
What is ABVC Biopharma Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
681.5k
USD
Based on the financial report for Dec 31, 2025, ABVC Biopharma Inc's Cash & Cash Equivalents amounts to 681.5k USD.
What is ABVC Biopharma Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-31%
Over the last year, the Cash & Cash Equivalents growth was 174%. The average annual Cash & Cash Equivalents growth rates for ABVC Biopharma Inc have been 96% over the past three years , -31% over the past five years .
